Dyadic Announces Third Quarter 2026 Financial Results and Recent Developments
Globe Newswire•12/11/2026•16:05 ET
0
Key Highlights
- ➤Cash position $6.05M at September 30, down from $8.59M year-end 2025
- ➤Q3 revenue $449,101, down 61.4% year over year
- ➤Q3 net loss $1.36M, or $0.04 per share, versus $1.98M loss
- ➤Dyadic recorded its first direct commercial product sales, primarily transferrin and DNase I
- ➤Camel chymosin milestone expected to generate $225,000 revenue in Q4 2026
Expert Statements
Joe Hazelton, President and Chief Operating Officer of Dyadic International
“During the third quarter, we reached a key commercialization milestone for our animal-free protein portfolio, advancing market adoption through initial product sales and growing customer engagement across the food, life sciences, and biopharmaceutical sectors.”
Joe Hazelton, President and Chief Operating Officer of Dyadic International
“While early sales remain modest and evaluation timelines are longer than anticipated, we are seeing increased sampling requests—particularly for transferrin—as we convert initial qualifications into potential business.”
Joe Hazelton, President and Chief Operating Officer of Dyadic International
“Concurrently, partner-led commercialization is building momentum.”
Joe Hazelton, President and Chief Operating Officer of Dyadic International
“Looking ahead, we are placing greater emphasis on larger strategic partnerships and collaborations, licensing and supply arrangements, and other potential transactions involving our platforms, products, and commercial programs.”
Joe Hazelton, President and Chief Operating Officer of Dyadic International
“We continue to evaluate all options to optimize the value of our platforms and assets, including financing alternatives and other opportunities aimed at strengthening our balance sheet, accelerating commercialization and maximizing shareholder value.”
Advances Commercialization, Expands Strategic Partnerships and Accelerates Biopharmaceutical Platform Validation
Dyadic to host earnings call on November 12, 2026, at 5:00 p.m. ET
Get started
Create a free account to read the full story.